arrow
M

Murray D. Norris

children's cancer institute
H指数:61
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Inclusion of JNK-independent drugs within multiagent chemotherapy improves response in relapsed high-risk neuroblastoma

在多药联合化疗中加入JNK非依赖性药物可改善复发高风险神经母细胞瘤的治疗反应

2025-11-280
PRE
P-glycoprotein as a chemotherapy resistance mechanism and biomarker of poor response in high-risk neuroblastoma
2025-11-010
OA
Polyamine depletion limits progression of acute leukaemia
2025-02-220
PRE
Golgi-localized Ring Finger Protein 121 is necessary for MYCN-driven neuroblastoma tumorigenesis

高尔基体定位的环指蛋白121是MYCN驱动的神经母细胞瘤肿瘤发生所必需的

2024-10-140
OAAI
The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis

转录共阻遏物Runx1t1对于MYCN驱动的神经母细胞瘤肿瘤发生至关重要

2024-07-111
OAAI
Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial
2024-01-105
OA
Addition of AMXT1501 (polyamine uptake inhibitor) plus DFMO (polyamine synthesis inhibitor) to standard-of-care chemotherapy/anti-GD2 antibody in the TH-MYCN mouse neuroblastoma model, enhances efficacy compared to addition of DFMO alone
2023-12-010
PRE
Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia
2023-05-179
PRE
Memory of stochastic single-cell apoptotic signaling promotes chemoresistance in neuroblastoma
2023-03-038
OAAI
Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma
2022-11-1710
OA
Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions
2022-06-015
OA
The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression

Curaxin CBL0137和组蛋白去乙酰化酶抑制剂Panobinostat的组合延缓了KMT2A-Rearranged白血病的进展

2022-05-239
OAAI